Collect Product
Product Details
Product Details
Human iPSC-Derived Cardiac Organoids (Cat. No. CIPO-HWL01) are three-dimensional in vitro models that recapitulate key structural and functional features of human cardiac tissue. These organoids are generated from the human iPSC line ATCC-HYR0103 under ultra-low attachment (ULA) culture conditions using a self-assembly cardiac differentiation workflow. Human iPSC-Derived Cardiac Organoids are shipped at ambient temperature and provided in a ready-to-use format for functional assessment and downstream applications. These organoids typically form cavity-containing cardiac structures, exhibit spontaneous contractile activity, and express markers associated with cardiomyocytes (cTnT), fibroblasts (VIM), and endothelial cells (CD31). Human iPSC-Derived Cardiac Organoids are intended for use with Human iPSC-Derived Cardiac Organoid Maintenance Medium (RIPO-HWM01). They are recommended for use between DIV 25 and DIV 50.
Product Specification
The cardiac organoids are ready-to-use organoids that are delivered in shipping medium and has to go through a recovery period according to instruction before starting any test or experiment.
Storage
After recovery, please store the organoid in its maintenance medium under the correct incubation condition and medium changing process.
Shipping
This product is supplied and shipped with blue ice, please inquire the shipping cost.
- *Please note that to support full process of organoid culture and maintenance, this product have to be used with hiPSC-Derived Cardiac Organoid Maintenance Kit (Cat. No.RIPO-HWM01),you can follow this link for product information.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
Product Diagram
Diagram of cardiac organoid differentiation.
Marker Expression
Cardiac Lineage Marker Expression in hiPSC-Derived Cardiac Organoids.
Day 30 human iPSC-derived cardiac organoids expressed key cardiac lineage markers, including cardiomyocyte markers cTnT (QC), MYL7, and MYL2; the fibroblast-associated marker Vimentin (QC); the endothelial marker CD31 (QC); and the smooth muscle marker α-SMA. These results indicate the presence of multiple cardiac-relevant cell populations within the 3D organoid structure.
ProtocolOrganoid Activity
Intra-batch morphological consistency
Cardiac organoids within the same batch showed comparable growth and morphological progression from Day 0 to Day 30, with low coefficients of variation (CVs) in diameter (QC), area, and circularity.
Inter-batch morphological consistency
Cardiac organoids from three independent batches showed comparable morphology, diameter (QC), area, and circularity, with low coefficients of variation (CVs).
ProtocolProtocolOrganoid Application
Spontaneous calcium transients in hiPSC-derived cardiac organoids
Representative calcium fluorescence image and ΔF/F₀ traces from hiPSC-derived cardiac organoids (in video). Spontaneous calcium transients were detected over a 60-s recording period and showed reproducible rhythmic activity. Quantification of a representative transient demonstrated a time to peak (TTP) of 0.5 ± 0.2 s and a calcium transient duration at 90% decay (CaD90) of 0.73 s. Scale bar: 500 μm.
Electrophysiological profiling of hiPSC-derived cardiac organoids by MEA
MEA recordings (QC) showed stable electrical activity across multiple electrodes in cardiac organoids. Following treatment with E-4031, a hERG/IKr potassium channel blocker, and nifedipine, an L-type calcium channel blocker, the organoids showed compound-related changes in MEA-derived electrophysiological readouts, supporting the potential use of this model for cardiac functional and safety assessment.
ProtocolProtocol
User Reviews Publish Comment
Contact Us
Drug Candidate Licensing
